Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Boehringer Ingelheim
Julphar
Cipla
McKesson

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,786,133

« Back to Dashboard

Which drugs does patent 7,786,133 protect, and when does it expire?

Patent 7,786,133 protects MOVANTIK and is included in one NDA.

This patent has forty patent family members in twenty-three countries.

Summary for Patent: 7,786,133
Title:Chemically modified small molecules
Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
Inventor(s): Bentley; Michael D. (Huntsville, AL), Viegas; Tacey X. (Madison, AL), Goodin; Richard R. (Fayerville, TN), Cheng; Lin (Huntsville, AL), Zhao; Xuan (Huntsville, AL)
Assignee: Nektar Therapeutics (San Carlos, CA)
Application Number:11/015,196
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,786,133
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,786,133
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,786,133

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,786,133

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004299138 ➤ Sign Up
Australia 2010202277 ➤ Sign Up
Australia 2012227249 ➤ Sign Up
Australia 2014280956 ➤ Sign Up
Canada 2549730 ➤ Sign Up
Canada 2758460 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chubb
Medtronic
Mallinckrodt
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.